Reproductive-Age Microbiome and Fertility: Mechanisms, Clinical Implications, and Emerging Therapies

Abstract

The complex interplay between the human microbiome and reproductive health is increasingly recognized as a critical factor influencing fertility in individuals of reproductive age. This comprehensive review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical presentations, diagnostic approaches, treatment modalities, and recent advances pertaining to the role of the microbiome in reproductive-age fertility. Emphasis is placed on mechanistic insights, clinical relevance, and guideline-based management strategies, providing healthcare professionals with an up-to-date resource for optimizing fertility outcomes through microbiome-informed interventions.

Introduction

Infertility affects up to 15% of couples worldwide and is a multifactorial condition influenced by genetic, hormonal, environmental, and increasingly, microbiome-related factors. The microbiome, encompassing the diverse community of microorganisms inhabiting various body sites, has emerged as a key modulator of reproductive health. While traditional fertility assessment has focused on hormonal and anatomical evaluations, recent research highlights the impact of the vaginal, endometrial, seminal, and gut microbiomes on reproductive outcomes. Understanding these associations is imperative for clinicians seeking to enhance fertility care through precision medicine.

Epidemiology / Disease Burden

Globally, infertility remains a significant public health challenge, with an estimated 48 million couples affected. Epidemiological studies have demonstrated that dysbiosis an imbalance in microbial communities of the genital tract is associated with a range of reproductive complications, including bacterial vaginosis (BV), pelvic inflammatory disease (PID), endometritis, and adverse pregnancy outcomes. In women, abnormal vaginal microbiota, particularly a reduction in Lactobacillus species, has been linked to decreased conception rates and increased miscarriage risk. In men, seminal microbiome alterations correlate with sperm parameter abnormalities and subfertility. These findings underscore the microbiome’s potential role in the observed disease burden of infertility.

Pathophysiology

The reproductive tract microbiome exerts multifaceted effects on fertility through modulation of local immunity, barrier integrity, and inflammatory responses. In women, Lactobacillus-dominated vaginal microbiomes maintain acidic pH and inhibit pathogenic overgrowth, thereby protecting against infections that compromise endometrial receptivity and embryo implantation. Disruption of this balance via overgrowth of anaerobes such as Gardnerella, Atopobium, and Prevotella can trigger pro-inflammatory cascades, impair sperm viability, and interfere with endometrial receptivity. In men, seminal microbiome dysbiosis may contribute to oxidative stress, DNA fragmentation, and impair spermatogenesis. Additionally, the gut-reproductive tract axis, mediated by circulating metabolites and immune signaling, plays a crucial role in modulating systemic inflammatory states that impact fertility.

Risk Factors

Numerous factors predispose individuals to reproductive tract dysbiosis, including antibiotic exposure, hormonal contraceptives, douching, poor sexual hygiene, high-risk sexual behaviors, and underlying systemic diseases such as diabetes mellitus. Lifestyle factors, such as diet high in refined carbohydrates and low in fiber, can also alter the gut and genital tract microbiota. Iatrogenic interventions such as assisted reproductive technologies (ART), intrauterine device (IUD) placement, and frequent gynecological procedures may disrupt native microbial communities, further increasing the risk of infertility.

Clinical Features

Microbiome-mediated reproductive dysfunction may manifest as recurrent pregnancy loss, unexplained infertility, recurring vaginal or seminal infections, and poor ART outcomes. In females, clinical signs often include abnormal vaginal discharge, odor, discomfort, or intermittent pelvic pain typically associated with BV or PID. In males, symptoms may be subtle but can include altered semen quality, decreased sperm motility, or persistent urethral discomfort. However, many patients may remain asymptomatic, emphasizing the need for a high index of suspicion in unexplained infertility cases.

Diagnosis

Diagnosis of reproductive microbiome disturbances relies on a combination of clinical assessment and laboratory techniques. Traditional methods include Gram staining, Amsel criteria, and Nugent scoring for BV, as well as semen analysis for male factor infertility. Advanced diagnostics utilize 16S rRNA gene sequencing, quantitative PCR, and next-generation sequencing to profile microbial communities with greater sensitivity and specificity. These tools enable clinicians to identify dysbiosis at an early stage and to stratify patients based on risk, thus informing personalized management strategies.

Treatment & Management

Management of microbiome-related infertility involves restoration of microbial balance and mitigation of risk factors. First-line interventions include targeted antibiotic therapy for pathogenic overgrowth (e.g., metronidazole for BV), followed by probiotic supplementation to re-establish Lactobacillus predominance. In men, empirical treatment of genital tract infections and lifestyle modifications such as improved dietary habits and cessation of harmful sexual practices are recommended. For couples undergoing ART, pre-treatment screening and modulation of the reproductive tract microbiome may improve implantation and live birth rates. Multidisciplinary approaches involving reproductive endocrinologists, microbiologists, and dietitians are increasingly advocated to optimize fertility outcomes through comprehensive care.

Recent Advances / Emerging Therapies

Recent years have seen significant advances in understanding and manipulating the reproductive microbiome. Novel therapeutics under investigation include next-generation probiotics, vaginal microbiome transplants, and prebiotic formulations designed to promote beneficial microbial colonization. Personalized medicine approaches such as microbiome profiling and targeted modulation are being integrated into reproductive health clinics to enhance ART success rates. Moreover, research into the gut-reproductive axis has opened avenues for systemic interventions, including dietary modifications and fecal microbiota transplantation in select cases. Ongoing clinical trials are expected to refine these strategies and establish evidence-based protocols for microbiome-informed fertility care.

Guideline Recommendations

Professional societies, including the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE), recognize the emerging role of the microbiome in reproductive health. Current guidelines recommend screening for and treating genital tract infections in infertile couples, especially prior to ART procedures. While routine microbiome profiling is not yet standard practice, clinicians are encouraged to consider microbiome assessment in cases of recurrent implantation failure, unexplained infertility, and recurrent pregnancy loss. Continued research and guideline updates are anticipated as the field evolves.

Conclusion

The reproductive-age microbiome is an integral determinant of fertility, influencing key biological processes and clinical outcomes. Advances in microbiome science offer promising opportunities for personalized diagnosis, targeted therapy, and improved fertility management. Ongoing research, interdisciplinary collaboration, and evidence-based practice are essential to fully realize the clinical potential of microbiome-informed reproductive care in contemporary medicine.